Page 205 - 2019_06-Haematologica-web

Running Title
patients with lung cancer: FRAGMATIC
trial. J Clin Oncol. 2016;34(5):488-494.
55. Panizo E, Alfonso A, García-Mouriz A, et al. Factors influencing the use of thrombo- prophylaxis in cancer outpatients in clinical practice: A prospective study. Thromb Res.
2015;136(6):1145-1148.
56. Papaxoinis G, Kamposioras K, Germetaki
T, et al. Predictive factors of thromboem- bolic complications in patients with esoph- agogatric adenocarcinoma undergoing pre- operative chemotherapy. Acta Oncol. 2018; 57(6):1-9.
57. Park K, Ryoo B-Y, Ryu M-H, et al. Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study. World J Gastrointest Oncol. 2017;9(4):176-183.
58. Patel JN, Jiang C, Hertz DL, et al. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015;121(7):1025-1031.
59. Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: Outcomes from the CONKO-004 trial. J Clin Oncol. 2015;33(18):2028-2034.
60. Sanchez Petitto G, Escalante CP, Richardson MN, Rojas Hernandez C. mod- ified Khorana models for prediction of can- cer-associated venous thromboembolism: an exploratory study. Blood. 2017; 130(Suppl 1):4635.
61. Posch F, Riedl J, Reitter E-M, et al.
Hypercoagulabilty, venous thromboem- bolism, and death in patients with cancer. Thromb Haemost. 2016;115(04):817-826.
62. Ramos JD, Casey MF, Bamias A, et al. The Khorana Score in predicting venous throm- boembolism for patients with metastatic urothelial carcinoma and variant histology treated with chemotherapy. Clin Appl Thromb. 2017; 23(7):755-760.
a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol. 2015;33(6):582-587.
69. Tafur AJ, Dale G, Cherry M, et al. Prospective evaluation of protein C and factor VIII in prediction of cancer-associat- ed thrombosis. Thromb Res. 2015; 136(6):1120-1125.
70. van Es N, Di Nisio M, Cesarman G, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: A prospective cohort study. Haematologica. 2017;102(9):1494-1501.
71. van Es N, Franke VF, Middeldorp S, Wilmink JW, Büller HR. The Khorana score for the prediction of venous thromboem- bolism in patients with pancreatic cancer. Thromb Res. 2017;150:30-32.
72. Vathiotis I, Dimakakos EP, Boura P, et al. Khorana Score: new predictor of early mor- tality in patients With lung adenocarcino- ma. Clin Appl Thromb. 2018;24(8):1347- 1351.
73. Wang Y, Attar BM, Fuentes HE, Yu J, Zhang H, Tafur AJ. Performance of Khorana Risk Score for prediction of Venous thromboem- bolism in patients with hepatocellular car- cinoma. Clin Appl Thromb Hemost. 2018; 24(3):471-476.
74. Yust-Katz S, Mandel JJ, Wu J, et al. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol. 2015;124(1):87-94.
75. Zahir MN, Shaikh Q, Shabbir-Moosajee M, Jabbar AA. Incidence of venous throm- boembolism in cancer patients treated with cisplatin based chemotherapy - a cohort study. BMC Cancer. 2017;17(1):1-8.
63. Ruch JM, Bellile E, Hawley AE, Anderson MA, Wakefield TW, Sood SL. Prediction of venous thromboembolism (VTE) in patients with Pancreatic cancer using clini- cal data, biomarkers, and VTE risk models. Blood. 2012;120(21):3398.
64. Rupa-Matysek J, Gil L, Kaźmierczak M, Barańska M, Komarnicki M. Prediction of venous thromboembolism in newly diag- nosed patients treated for lymphoid malig- nancies: validation of the Khorana Risk Score. Med Oncol. 2018;35(1):1–8.
65. Rupa-Matysek J, Lembicz M, Rogowska EK, Gil L, Komarnicki M, Batura-Gabryel H. Evaluation of risk factors and assess- ment models for predicting venous throm- boembolism in lung cancer patients. Med Oncol. 2018;35(5):1-10.
66. Santi RM, Ceccarelli M, Bernoccol E, et al. Khorana score and histotype predicts inci- dence of early venous thromboembolism in non-Hodgkin lymphomas. Thromb Haemost. 2017;117(8):1615-1621.
67. Sohal DPS, Kuderer NM, Shepherd FA, et al. Predictors of venous thmromboem- bolism in colorectal cancer: results from a global prospective study. Blood. 2016; 128(22):1422.
68. Srikanthan A, Tran B, Beausoleil M, et al. Large retroperitoneal lymphadenopathy as
haematologica | 2019; 104(6)
1287